Targeting the NF-κB pathway in cancer therapy.
Most NF-κB inhibitors target the IKK complex, IκB proteins, or NF-κB transcription factors. The most promising classes of inhibitors include antioxidants, antiinflammatory compounds, natural compounds, statins, proteasome inhibitors, IKKβ inhibitors, biologics, gene therapy, and RNA interference. Targeting NF-κB is limited by intrinsic pathway complexity, cross-talk with other pathways, a lack of biomarkers, poor drug specificity, drug resistance, and difficulty with drug delivery. Future NF-κB targeting will be improved through better understanding of the pathway, more specific inhibitors, and multimodality therapies.